Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 529

1.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

JAMA. 2011 Dec 7;306(21):2340-7. doi: 10.1001/jama.2011.1671. Epub 2011 Nov 6.

PMID:
22056397
2.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
3.

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 May;68(5):635-41. doi: 10.1136/ard.2007.087411. Epub 2008 Apr 15.

PMID:
18413443
4.

Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.

Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):253-62. doi: 10.1002/acr.22112.

5.

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.

Arthritis Rheum. 2003 Apr;48(4):1093-101.

6.

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.

Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

Ann Rheum Dis. 2013 May;72(5):721-7. doi: 10.1136/annrheumdis-2011-201060. Epub 2012 Jun 23.

PMID:
22730374
7.

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.

Ann Rheum Dis. 2009 Apr;68(4):519-25. doi: 10.1136/ard.2007.087593. Epub 2008 Apr 15.

PMID:
18413440
8.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.

J Rheumatol. 2011 Oct;38(10):2258-63. doi: 10.3899/jrheum.110145. Epub 2011 Aug 15.

PMID:
21844151
9.

Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.

Yeh KW, Lee CM, Chang CJ, Lin YJ, Huang JL.

PLoS One. 2014 Mar 6;9(6):e90757. doi: 10.1371/journal.pone.0090757. eCollection 2014.

10.

Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.

Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, Hull RG, Venning HE, Rahman JK, Cummins CL; British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register.

Rheumatology (Oxford). 2011 Jan;50(1):189-95. doi: 10.1093/rheumatology/keq308. Epub 2010 Nov 3.

PMID:
21047801
11.

Clinical remission in juvenile idiopathic arthritis after termination of etanercept.

Postępski J, Kobusińska K, Olesińska E, Osińska V, Opoka-Winiarska V.

Rheumatol Int. 2013 Oct;33(10):2657-60. doi: 10.1007/s00296-012-2468-3. Epub 2012 Jul 21.

12.

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Apr;52(4):712-7. doi: 10.1093/rheumatology/kes373. Epub 2012 Dec 24.

PMID:
23267169
13.

Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis.

Haapasaari J, Kautiainen H, Hannula S, Pohjankoski H, Hakala M.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6):867-70.

PMID:
12508784
14.

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.

15.

Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.

Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.

Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145.

16.

A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.

Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F.

Clin Exp Rheumatol. 2010 Nov-Dec;28(6):919-22. Epub 2011 Jan 4.

PMID:
21205467
17.

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.

Anink J, Prince FH, Dijkstra M, Otten MH, Twilt M, ten Cate R, Gorter SL, Koopman-Keemink Y, van Rossum MA, Hoppenreijs EP, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2015 Nov;54(11):1964-9. doi: 10.1093/rheumatology/kev195. Epub 2015 Jun 14.

PMID:
26078219
18.

Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.

Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR; British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.

Rheumatology (Oxford). 2015 Jul;54(7):1279-85. doi: 10.1093/rheumatology/keu489. Epub 2015 Jan 30.

PMID:
25638806
19.

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2014 Jun;73(6):1114-22. doi: 10.1136/annrheumdis-2012-203046. Epub 2013 May 21.

20.

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Sep;52(9):1674-9. doi: 10.1093/rheumatology/ket170. Epub 2013 Jun 4.

PMID:
23740187

Supplemental Content

Support Center